On January 11, 2022 Neogene Therapeutics, Inc., a biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies to treat cancer, reported an exclusive, worldwide license agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer (Press release, Neogene Therapeutics, JAN 11, 2022, View Source [SID1234598572]). These TCRs were discovered in the laboratory of Steven Rosenberg, M.D., Ph.D., Chief of Surgery at the NCI and a pioneer in the fields of immunotherapy and gene therapy for patients with advanced cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This portfolio of TP53 and KRAS targeted T cell therapies complements Neogene’s proprietary neoantigen TCR discovery and T cell engineering platform. Neogene’s platform aims to identify neoantigens and suitable TCRs to target for individual patients and enable the engineering of T cells with these neoantigen-specific TCRs for patients suffering from a broad spectrum of solid tumors.
"TP53 and KRAS are among the most commonly mutated genes in cancer, however, very few therapies specifically targeting these mutations are currently available, and there is a high unmet need for effective treatment options," said Raphaël Rousseau, M.D., Ph.D., Chief Medical Officer of Neogene Therapeutics. "We’re excited to have entered into this agreement with the NIH to expand our current development program and address this need through the development of TCR-engineered T cell therapies for patients with tumors that harbor these common mutations."
Neogene has been granted worldwide rights to develop, manufacture and commercialize this TCR portfolio of autologous and allogeneic T cell therapy product candidates that are engineered with CRISPR technology for the treatment or prevention of cancer.
"Adding these TCRs to our pipeline will enable Neogene to flexibly develop them alone or in combination with individualized neoantigen TCR cell therapies, providing us with the opportunity to diversify our pipeline and potentially target multiple neoantigens in individual patients," said Carsten Linnemann, Ph.D., President, Chief Executive Officer and Co-Founder of Neogene Therapeutics. "This is a strategic step toward strengthening Neogene’s breadth and position as a global leader in the development of TCR therapies for the treatment of solid cancers."
Pursuant to the terms of the license agreement, Neogene will provide an upfront payment and certain clinical, regulatory, and sales milestone payments, as well as royalties on net sales of products covered by the license.